LC3B upregulation in NANOG promotes immune resistance through stimulating over-activation of EGFR signaling, and the NANOG-LC3B-EGFR axis is a key factor in controlling NANOG immune-refractory cancers as a central molecular target [96]. Here, MAP1LC3B is linked to cancer.